Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Charles Schoch as Chief Financial Officer (CFO). Mr. Schoch, who has served as interim CFO of Candel since January 2024, will transition to the CFO role permanently, effective immediately.
'Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO,' said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. 'He has effectively supported our strategic priorities in a complex market environment while maintaining disciplined capital management. His deep understanding of our business will continue to be instrumental as we advance our clinical pipeline, prepare for our Biologics License Application submission for CAN-2409 in localized prostate cancer, and execute on our near- and long-term corporate goals.'
Since joining Candel in November 2021, Mr. Schoch has served in various financial reporting and accounting positions of increasing responsibility, most recently as VP of Finance and Corporate Controller, before being named interim CFO in January 2024. In his interim CFO role, Mr. Schoch developed significant investment banking relationships and has led the company through engagements with top-tier institutional investors, culminating in a previously-announced capital raise with net proceeds of approximately $86 million following the disclosure of positive results in the phase 3 clinical trial of CAN-2409 in localized prostate cancer in December 2024. In January 2025, he was promoted to Senior VP. During his time at Candel, Mr. Schoch has built a high-performing finance function that oversees Candel's financial close process, internal controls, SEC reporting, financial planning, procurement, payroll, and treasury operations. Mr. Schoch has also worked closely with Candel's executive leadership team on investor relations, business development, and financing initiatives.
Prior to joining Candel, Mr. Schoch served as Corporate Controller at Corbus Pharmaceuticals from 2019 to 2021. Before Corbus, he spent seven years in PwC's Health Industry assurance practice where he served a diverse group of audit clients, ranging from pre-IPO to multinational public companies within the life sciences sector. Earlier in his career, Mr. Schoch worked for several Third Rock Venture portfolio companies as a financial and operational consultant. Mr. Schoch holds an M.B.A. and M.S.A. from Northeastern University and a B.S. in business administration with a concentration in finance from Elon University.
'I am honored to continue serving in this role and excited about the opportunities that lie ahead for Candel,' commented Mr. Schoch. 'Our strong financial foundation and disciplined approach to capital allocation and value creation position us well for sustainable growth. As we advance our promising clinical pipeline and prepare for key milestones, my focus remains on maintaining financial stability while strategically investing in our future. I look forward to working with our talented team on our goals of driving value for our stakeholders and ultimately helping to deliver clinically meaningful solutions to cancer patients in need.'
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform.
The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA most recently also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC.
CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, expectations regarding the submission of the BLA for CAN-2409 in intermediate-to-high-risk localized prostate cancer; and expectations regarding the therapeutic benefit of the Company's platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact:
Theodore Jenkins
VP, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Globe and Mail

31 minutes ago

• Globe and Mail

MicroStrategy Stock Trades 32% Below 52-Week High: Buy, Sell or Hold?

MicroStrategy MSTR, doing business as 'Strategy,' shares closed at $369.70 on Friday, 32% below the 52-week high of $543 it hit on Nov. 21, 2024. Strategy shares have appreciated 27.6% year to date (YTD), while the Zacks Computer - Software industry and Zacks Computer and Technology sector have returned 10.4% and 0.9%, respectively. Strategy is the world's largest bitcoin treasury company, holding 592,100 bitcoins as of June 15, 2025. In early June, Strategy acquired 10,100 bitcoins for $1.05 billion. MARA Holdings MARA, Riot Platform RIOT and Tesla TSLA are other well-known companies that hold bitcoins in their respective balance sheets. As of March 31, MARA Holdings and Riot Platforms had 47,531 and 19,223 bitcoins, respectively, while Tesla had 11,509 bitcoins at the end of the first quarter of 2025. Strategy shares have outperformed MARA Holdings, Riot Platform and Tesla, shares of which have dropped 14.6%, 6.4% and 20.3%, YTD. MSTR Stock's Performance MSTR stock is currently trading above the 200-day moving average, indicating a bullish trend. MSTR Stock Trades Above 200-Day SMA MSTR Benefits From Growing Bitcoin Holding Strategy benefits from the Trump administration's announcement of the establishment of a strategic bitcoin reserve. Bitcoin, the most popular cryptocurrency, has been soaring due to increasing acceptance as a non-sovereign asset, as well as higher institutional and corporate adoption. However, bitcoin's volatility is a headwind for MSTR. Bitcoin is now trading above $101K, much lower than the $111K it registered in May. MSTR benefits from increasing bitcoin yield, 13.7% year to date (as of April 28, 2025), keeping the company on track to reach full year target of 15%, which is now raised to 25% and bitcoin dollar gain target to $15 billion (up from initial target of $10 billion). Bitcoin gains in dollar terms were $4.1 billion in the first quarter of 2025 and $5.8 billion as of April 28, 2025. The company's disciplined approach to capital raising through preferred equity offerings — Strike (8% convertible preferred is trading with an effective yield of roughly 9%) and Strife (10% fixed coupon perpetual preferred) — is a key catalyst. As of April 28, 2025, MSTR raised $6.6 billion through equity offerings and $3.4 billion through fixed income ($2 billion from convertible notes, $0.7 billion each through Strike and Strife). Strategy has issued $20.9 billion in equities and $6.4 billion in fixed income securities as part of its 21/21 plan since Oct. 30, 2024. The company has $14.6 million remaining under fixed income securities and $0.1 million under equities as part of the existing plan. Strategy currently plans to raise $42 billion through equity issuance and $42 billion through fixed income securities by the end of 2027. Under the current plan, the company has $21.1 billion in equity and $35.6 billion in fixed income securities remaining to be issued. Growing Subscription Revenues Aid MSTR Prospects Strategy is benefiting from growing software subscription revenues that surged 62% year over year to $37.1 million and accounted for 33% of first-quarter 2025 total revenues. Subscription billings grew 38% year over year to $24.5 million. The company benefits from continuing cloud demand with its flagship Strategy One that powers some of the largest analytics deployments in the world. Strategy One supports varied industries, including retail, banking, technology, manufacturing, insurance, consulting, healthcare, telecommunications, and the public sector. Strategy is leveraging generative AI to automate and accelerate the deployment of AI-enabled applications across enterprises. Strategy's rich partner base that includes the likes of Amazon Web Services, Microsoft, STACKIT, and Google is a growth driver. Earnings Estimates Revision Trend Steady for MSTR For second-quarter 2025, the Zacks Consensus Estimate for MSTR's loss has been steady at 12 cents per share over the past 30 days. The company reported a loss of 76 cents in the year-ago quarter. For 2025, the Zacks Consensus Estimate for MSTR's loss has been steady at $15.73 per share over the past week. The company reported a loss of $6.72 per share in 2024. Here's Why MSTR Stock is a Hold Now Strategy shares are overvalued, as suggested by the Value Score of F. In terms of Price/Book, Strategy is trading at 3.0X compared with MARA's 1.35X and Riot Platforms' 1.16X, suggesting a premium valuation. MSTR Vs. MARA Valuation MSTR Vs. RIOT Valuation Image Source: Zacks Investment Research Strategy benefits from its growing bitcoin holdings and increasing subscription revenues. However, challenging macroeconomic conditions and uncertainty about tariffs increase volatility in bitcoin trading. Stretched valuation is a concern. Strategy currently has a Zacks Rank #3 (Hold), which implies that investors should wait for a better entry point to accumulate the stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tesla, Inc. (TSLA): Free Stock Analysis Report MicroStrategy Incorporated (MSTR): Free Stock Analysis Report Marathon Digital Holdings, Inc. (MARA): Free Stock Analysis Report Riot Platforms, Inc. (RIOT): Free Stock Analysis Report

CTV News

37 minutes ago

• CTV News

Support for solar energy and offshore wind falls among Democrats and independents, AP-NORC poll says

Wind turbines stretch across the horizon at dusk at the Spearville Wind Farm, Sept. 29, 2024, near Spearville, Kan. (AP Photo/Charlie Riedel, File) Americans' support for green energy tax credits and renewable energies like wind and solar power has decreased in recent years, according to a new poll, driven by a softening in support from Democrats and independents. The poll from The Associated Press-NORC Center for Public Affairs Research finds that U.S. adults' support for tax credits for electric vehicles and solar panels has weakened, as well as their enthusiasm for offshore wind farm expansion. While Democrats remain the strongest supporters of these initiatives, the poll reveals signs of growing cynicism within their ranks. The poll results coincide with sweeping changes President Donald Trump's Republican administration is making to regulations related to energy and climate change, including slashing the federal workforce in these departments. And although Democrats and independents have weakened their support for some green energy initiatives, there has not been an increase in support for Trump's energy policies. The poll found only about four in 10 U.S. adults, including only one in 10 Democrats, about two in 10 independents and three-quarters of Republicans, approve of the way Trump is handling climate change, which largely tracks with his overall approval rating. Democrats and independents drive decline in support for renewable energy credits About six in 10 Democrats, 58 per cent, favour tax credits for purchasing an electric vehicle, down from about seven in 10 in 2022. Among independents, support declined from 49 per cent in 2022 to 28 per cent. Only one-quarter of Republicans supported this policy in 2022, and that hasn't changed measurably. 'As far as the pollution goes ... the vehicles nowadays put out very little emissions to the air,' said JD Johnson, a 62-year-old Democrat from Meadowview, Virginia, who somewhat opposes tax credits to purchase an electric vehicle. That's partly because he sees the electric vehicle manufacturing process as energy intensive and believes gasoline-powered vehicles have made improvements with the pollutants they emit. The decline in favoring solar panel tax credits was across the board rather than being concentrated among Democrats. 'For solar panels, in all honesty, I don't think they're that efficient yet,' said Glenn Savage, 78, a left-leaning independent from Rock Hill, South Carolina. 'I'd rather see them pour money into research and try to get the solar panels more efficient before they start giving tax breaks to the public. I may be wrong on that, but that's just my thought.' Scientists say transitioning to renewable energies and ditching fossil fuels that release planet-warming emissions are essential to protect the planet. Billions of dollars in project grants for clean technologies awarded during President Joe Biden's Democratic administration have been canceled by the Trump administration, and the offshore wind sector has been stunted by Trump's executive order that paused approvals, permits and loans for wind energy projects. Fewer than half of U.S. adults, 44 per cent, now say that offshore wind farms should be expanded in the U.S., down from 59 per cent in 2022. About half favor expanding solar panel farms, while about two-thirds were in support in 2022. When people are concerned about the economy and their personal finances, environmental issues are sometimes prioritized less, said Talbot Andrews, an assistant professor in the department of government at Cornell University who was not involved in the poll. 'I think it makes people anxious to think about increased taxes or increased spending on environmental issues when the cost of eggs are going through the roof,' Andrews said. Low support for Trump's efforts to expand offshore drilling and coal mining Trump has championed the expansion of offshore oil drilling, as well as domestic coal production. Despite a decline in support for expanded renewable energies, the new poll shows that only about one-third of U.S. adults think offshore drilling for oil and natural gas should be expanded in the U.S., and only about one-quarter say this about coal mining. In both cases, Republicans are much more likely than Democrats to support expanding these energy sources. Trump has sought to open up national monuments for oil drilling, but more U.S. adults oppose than support auctioning off more public space for oil drilling. Only about one-quarter of U.S. adults favor this, while 4 in 10 are opposed. Republicans are much more likely than independents or Democrats to be in support. Bipartisan support for consumer rebates and home appliance ratings The Energy Star program that certifies appliances, such as dishwashers and refrigerators, as energy efficient recently appeared in headlines when the EPA made plans to scrap the program. The blue and white logo is well recognized, and experts say the program has long had bipartisan support until recently. The poll found three-quarters of Democrats support providing consumer rebates for efficient home appliances, compared with six in 10 Republicans. Patrick Buck, 54, from Chicago, describes himself as a liberal Republican and is a fan of the consumer rebates for energy-efficient appliances. 'It seems to work in terms of transforming what people have in their houses, because a lot of people have a lot of old appliances and just can't afford new ones,' he said. Safe air, water, meat and produce The poll found only about two in 10 U.S. adults are 'extremely' or 'very' confident in the federal government's ability to ensure the safety of their drinking water, the air they breathe and the meat, poultry, fruits and vegetables they buy in grocery stores. About four in 10 U.S. adults are 'somewhat' confident in the federal government's ability to ensure the safety of each of these, and about 4 in 10 are 'not very' or 'not at all' confident. The Trump administration has announced plans to roll back rules and policies related to limiting pollution and greenhouse gas emissions, such as rules that limit pollution from power plants and blocking California's efforts to phase out cars that run on gas. The federal government has also cut staff at the Food and Drug Administration, the federal agency tasked with protecting public health and ensuring food supply safety. ___ The AP-NORC poll of 1,158 adults was conducted June 5-9, using a sample drawn from NORC's probability-based AmeriSpeak Panel, which is designed to be representative of the U.S. population. The margin of sampling error for adults overall is plus or minus 4 percentage points. ___ The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. The AP is solely responsible for all content. Find the AP's standards for working with philanthropies, a list of supporters and funded coverage areas at Isabella O'malley And Amelia Thomson-deveaux, The Associated Press

Globe and Mail

an hour ago

• Globe and Mail

Greenway Technologies Announces Uplisting to OTCQB Venture Market

ARLINGTON, TX, June 23, 2025 (GLOBE NEWSWIRE) -- Greenway Technologies, Inc. (OTCQB: GWTI) ('Greenway'), an advanced gas-to-liquids ('GTL') and gas-to-hydrogen ('GTH') technology development company, announced today that it has successfully uplisted its common stock from the OTC ® Pink Market to the OTCQB ® Venture Market ('OTCQB'). The uplisting was processed and approved by OTC Markets Group Inc., and Greenway's common stock commenced trading on the OTCQB on June 20, 2025. Greenway will continue to trade under the ticker symbol 'GWTI.' To be eligible for the OTCQB, companies must be current in their reporting and must undergo an annual verification and management certification process. 'This is a significant milestone supporting the growth of Greenway with our uplisting to the OTCQB,' said Kevin Jones, President of Greenway. 'This reflects our commitment to enhancing transparency, increasing market visibility and providing enhanced opportunities for our shareholders. We expect our uplisting to the OTCQB ® to allow access to a broader investor base, attract institutional investors and improve liquidity for our stock.' About Greenway Technologies, Inc. Based in Arlington, Texas, Greenway, through its wholly owned subsidiary, Greenway Innovative Energy, Inc., is engaged in the research and development of proprietary GTL and GTH syngas conversion systems that can be scaled to meet oil and gas field production requirements, or the requirements of various processes where natural gas is produced or available. Greenway's patented technology has been integrated into its recently completed first-generation commercial G-Reformer ™ unit, a unique component used to convert natural gas into synthesis gas (a mixture of Hydrogen and Carbon Monoxide). In the case of hydrogen creation, an additional new technology, the H-Reformer ™, has been created which creates synthesis gas consisting of Hydrogen gas and CO 2. When combined with an FT reactor and catalyst, G-Reformer ™ units can be deployed to process a variety of natural gas streams, including pipeline gas, associated gas, flared gas, vented gas, coal-bed methane, and biomass to produce fuels including gasoline, diesel, jet fuel, and methanol as well as valuable chemical outputs. When derived from natural gas, these fuels are incrementally cleaner than conventionally produced oil-based fuels. Notice Regarding Forward-Looking Statements: This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading 'Risk Factors' in Greenway's most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the Securities and Exchange Commission (the 'SEC'), which are available on the SEC's website at Except as otherwise required by law, Greenway disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Contact: Kevin Jones, President Greenway Technologies, Inc. Investors & Analysts Contact: Greenway Investor Relations ir@ SEC filings can be found at: